RCS - Synairgen PLC - Business Update
Synairgen PLC has provided a business update regarding its Phase 2 (INVENT) clinical study for SNG001, an inhaled interferon-beta treatment for mechanically-ventilated patients with respiratory viruses. The company has established over 60 clinical study sites across the US, UK, and Europe, and has made significant progress in securing regulatory approvals, including FDA clearance for patient recruitment. Collaborations with partners and ongoing dialogue with respiratory experts are key to the study's success, with interim analysis expected in mid-2026 and final analysis in mid-2027.
London Stock Exchange·
